Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093710 | 0.88 | TACR1 (0.40) | TACR1 | |
| SCHEMBL4095896 | 0.67 | TSHR (0.44) | TACR1MAPTALDH1A1POLBTSHR | |
| SCHEMBL4637752 | 0.66 | CYP19A1 (0.74) | MAPTALDH1A1POLBTSHRTP53 | |
| SCHEMBL6091680 | 0.66 | PPARG (0.61) | — | |
| SCHEMBL20546618 | 0.65 | MEN1 (0.51) | MAPT | |
| SCHEMBL15497059 | 0.65 | CYP19A1 (0.47) | MAPTALDH1A1POLBTSHRATM | |
| SCHEMBL6857727 | 0.65 | PPARG (0.72) | MAPTPOLBTP53 | |
| SCHEMBL28366046 | 0.65 | TSHR (0.54) | MAPTALDH1A1POLBTSHRATM | |
| SCHEMBL1989200 | 0.65 | AR (0.64) | MAPTALDH1A1POLBTSHRTP53 | |
| SCHEMBL21264658 | 0.64 | TSHR (0.41) | MAPTALDH1A1POLBTSHRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | TACR1 1932/4885MAPT 54/4885ALDH1A1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.